Table 2.
The clinical characteristics at baseline, stratified by risk score in IHC validation group.
| Variable | Low risk | High risk | p-value |
|---|---|---|---|
| No. of patients | 49 | 46 | |
| Age | 0.866 | ||
| <60 | 11 (22.45%) | 11 (23.91%) | |
| ≥60 | 38 (77.55%) | 35 (76.09%) | |
| Gender | 0.052 | ||
| Male | 36 (73.47%) | 41 (89.13%) | |
| Female | 13 (26.53%) | 5 (10.87%) | |
| T stage | 0.266 | ||
| T1 | 2 (4.08%) | 1 (2.17%) | |
| T2 | 14 (28.57%) | 5 (10.87%) | |
| T3 | 29 (59.18%) | 35 (76.09%) | |
| T4 | 1 (2.04%) | 1 (2.17%) | |
| NA | 3 (6.12%) | 4 (8.70%) | |
| N stage | 0.005** | ||
| N0 | 30 (61.22%) | 17 (36.96%) | |
| N1 | 15 (30.61%) | 13 (28.26%) | |
| N2 | 2 (4.08%) | 14 (30.43%) | |
| N3 | 2 (4.08%) | 2 (4.35%) | |
| TNM stage | 0.093 | ||
| I | 5 (10.20%) | 1 (2.17%) | |
| II | 24 (48.98%) | 15 (32.61%) | |
| III | 14 (28.57%) | 25 (54.35%) | |
| IV | 3 (6.12%) | 3 (6.52%) | |
| NA | 3 (6.12%) | 2 (4.35%) | |
| Tumor grade | 0.084 | ||
| Well | 10 (20.41%) | 3 (6.52%) | |
| Poorly | 10 (20.41%) | 7 (15.22%) | |
| Moderately | 29 (59.18%) | 36 (78.26%) | |
| IHC area% of CD38 | <0.001*** | ||
| <1% | 10 (20.41%) | 33 (71.74%) | |
| ≥1% | 39 (79.59%) | 13 (28.26%) | |
| IHC score of INPP5E | 0.083 | ||
| <2 | 19 (38.78%) | 26 (56.52%) | |
| ≥2 | 30 (61.22%) | 20 (43.48%) | |
| IHC score of POLR3G | <0.001*** | ||
| <2 | 11 (22.45%) | 37 (80.43%) | |
| ≥2 | 38 (77.55%) | 9 (19.57%) | |
| Death at FU | 0.002** | ||
| No | 23 (46.94%) | 8 (17.39%) | |
| Yes | 26 (53.06%) | 38 (82.61%) | |
| OS | 40.98 ± 27.01 | 22.52 ± 23.52 | <0.001*** |
**p < 0.01; ***p < 0.001.